Categories

Biologics in the Emerging Markets – Ripe For Realization of the Commercial Potential – But Hurdles Still to Overcome

US$ 3900

Biologics cover a diverse range of products and deliverables and have revolutionized the treatment of many diseases. The complexity of biologics has made their manufacture an expensive and lengthy process which has hindered uptake in many less developed healthcare markets.

06-12 2015   Pages: 59

Accountable Care Organizations – A Building Block for the Future of Health Care

US$ 3900

The Accountable Care Act promoted ACOs through a variety of programs: Comprehensive Primary Care Initiative, Partnerships for Patients Initiative, Pioneer and Advanced Payment ACO Models and Medicare Shared Savings Program for ACOs.

06-12 2015   Pages: 53

Emerging Pharmaceutical Technologies – Stem cells

US$ 3900

Stem cell technology is set to play a significant role in the pharmaceutical industry of the future. The opportunities for using stem cells across drug discovery, disease research, drug development and treatments are wide-ranging, yet largely unproven at present.

06-12 2015   Pages: 53

Clinical Development and Trial Design – Developing a Coherent Approach From Beginning to End

US$ 3900

In today’s cost constrained environment, the clinical development plan can help refine the trial process, encouraging cost and time efficiencies and ensuring a streamlined process throughout.

06-12 2015   Pages: 48

Diversification in the Pharmaceutical Industry – Essential For Survival or an Unnecessary Distraction?

US$ 3900

Pharmaceutical companies face the dual threats of industry specific difficulties driven by the innovation crisis, patent expiries and healthcare reform, coupled with the more generalized issues caused by the continuing global economic slowdown.

06-12 2015   Pages: 57

The Payer Landscape in the United States – The Pharmaceutical Industry Faces a Rapidly Changing Marketplace

US$ 3900

Managed care began to be developed as early as 1917, with both private and government payers established by the mid-1960s. Medicare and Medicaid are the major government payers, with the health care reform legislation of 2010 providing changes for both.

06-12 2015   Pages: 53

Pharmaceutical Pricing Strategies – Changing approaches to meet challenging times

US$ 3900

The current economic environment has created a number of challenges within the pharmaceutical market, with governments looking to reduce spending on healthcare and drugs.

06-12 2015   Pages: 51

The Next Generation of Pharmaceutical Marketing Strategies – Understanding All of the Strategic Considerations Needed in the Age of Multiple Stakeholders

US$ 3900

Pharmaceuticals save lives. They prevent more serious, life changing conditions, they prevent surgery, and they improve the quality of life for many patients. The environment in which these products are developed and commercialized is in a period of great transformation.

06-12 2015   Pages: 46

Reformulation Strategies – New Technologies Extend Use Beyond Lifecycle Management

US$ 3900

Reformulation performs a key role in the pharmaceutical industry enabling companies to maximize their returns on investment while broadening treatment options and improving patient experience.

06-12 2015   Pages: 51

Looking at Senior Long-term Care – Where will the market go?

US$ 3900

In the last 50 years, long-term care facilities in the US have changed significantly. Many facilities are now Continuing Care Retirement Communities (CCRCs), offering a continuum of care from Independent Living to Assisted Living to Skilled Nursing.

06-12 2015   Pages: 50
Contact With Us
Join templatemonster at google+
Customized Research
Request Sample